Search results for: Lawrence H. Price

Items from 1 to 20 out of 117 results

article

Lithium and the kidney

Lawrence H. Price

The Brown University Psychopharmacology Update > 34 > 1 > 7 - 8

Lithium was the first drug to receive U.S. Food and Drug Administration (FDA) approval for the treatment of bipolar disorder, back in 1970. Although it's common knowledge that the Australian psychiatrist John Cade initially described lithium's anti‐manic efficacy in 1949, it's less well known that the FDA banned lithium that same year. This occurred following the deaths from lithium intoxication of...

article

Opioids and antidepressants: When is the mantra wrong?

Lawrence H. Price

The Brown University Psychopharmacology Update > 33 > 11 > 7 - 8

It's become a bit of a mantra that psychotropic drugs and opioids shouldn't be co‐prescribed. That shouldn't be surprising. As every reader of the Update surely knows, we are in the midst of an opioid overdose epidemic, with deaths involving any opioid, whether prescription or illicit, increasing by more than seven‐fold from 1999 to 2020. That's more than 564,000 deaths. For perspective: 68,630 Americans...

article

Pharmacogenetics and alcoholism: Reaching for the next level

Lawrence H. Price

The Brown University Psychopharmacology Update > 33 > 9 > 7 - 8

article

Mirtazapine for anxiety in autism

Lawrence H. Price

The Brown University Psychopharmacology Update > 33 > 7 > 7 - 7

article

Prediction is easy; change is hard

Lawrence H. Price

The Brown University Psychopharmacology Update > 33 > 5 > 7 - 7

As in my last commentary in the March issue, three studies in this month's issue of the Update struck me as especially comment‐worthy. This time, the common thread is obvious: ketamine. It's a topic that reminded me of a commentary I wrote back in July 2019, one I now look back on with no small measure of chagrin…

article

Psychopharmacology research: Pandemic reverberations

Lawrence H. Price

The Brown University Psychopharmacology Update > 33 > 3 > 7 - 7

As I perused the contents of this month's Update, three studies in particular struck me as calling out for comment. Two of them are worth noting because they are timely and, well, attention‐getting. The third is more conventionally notable, although as I thought about it, I realized it resonated in an unexpected way with the other two.

article

Time to demedicalize marijuana

Lawrence H. Price

The Brown University Psychopharmacology Update > 33 > 1 > 7 - 7

It seems like the intersection of public policy and psychopharmacology has been very crowded over the past 18 months. Given the events of the past couple of years and the scope of our field, I suppose that shouldn't be surprising. Maybe our colleagues in other medical disciplines feel the same way (I'm looking at you, infectious disease specialists). In any case, loath as I am to contribute to the...

article

Aducanumab: Boon or bust?

Lawrence H. Price

The Brown University Psychopharmacology Update > 32 > 11 > 7 - 7

article

The end of the buprenorphine waiver

Lawrence H. Price

The Brown University Psychopharmacology Update > 32 > 9 > 7 - 8

article

The perils of pandemic psychopharmacology

Lawrence H. Price

The Brown University Psychopharmacology Update > 32 > 7 > 7 - 7

Throughout the COVID‐19 pandemic we've heard story after story in the lay media about the terrible toll this worldwide catastrophe has exacted on our collective mental health. Some of these stories have focused on specific age groups (children, teens, the elderly), others on specific ethnic groups (indigenous peoples, minorities), still others on impacts for just folks in general (loneliness, existential...

article

The ghost of Heisenberg, or: methamphetamine, again

Lawrence H. Price

The Brown University Psychopharmacology Update > 32 > 5 > 7 - 7

article

Treating schizophrenia, part 2: What we can (almost) do now

Lawrence H. Price

The Brown University Psychopharmacology Update > 32 > 3 > 7 - 7

In my last commentary, for the January 2021 issue, I took a look at the American Psychiatric Association's new practice guideline for the treatment of schizophrenia and suggested that even the “truisms” contained in that committee‐generated pronouncement merited consideration by busy practicing clinicians. The bottom line of my assessment was that we should try to maximize, as best we can, the impact...

article

Treating schizophrenia: What we can do now

Lawrence H. Price

The Brown University Psychopharmacology Update > 32 > 1 > 7 - 7

If you are a regular reader of the American Journal of Psychiatry, you might have noticed at the back of a recent issue a brief article under the heading “APA Official Actions” announcing the publication of a new practice guideline for the treatment of schizophrenia, the third edition of this guideline since its inception in 1997. If you took the time to read the contents, you encountered some background...

article

The 2020 election commentary

Lawrence H. Price

The Brown University Psychopharmacology Update > 31 > 11 > 7 - 7

article

The COVID‐19 commentary

Lawrence H. Price

The Brown University Psychopharmacology Update > 31 > 9 > 7 - 8

article

Fast‐fail comes to psychopharmacology

Lawrence H. Price

The Brown University Psychopharmacology Update > 31 > 7 > 7 - 8

article

The conundrum of antipsychotics and mortality

Lawrence H. Price

The Brown University Psychopharmacology Update > 31 > 5 > 7 - 7

article

Memory as a therapeutic target for psychopharmacology

Lawrence H. Price

The Brown University Psychopharmacology Update > 31 > 3 > 7 - 7

article

Treating depression: Prediction in a time of change

Lawrence H. Price

The Brown University Psychopharmacology Update > 31 > 1 > 7 - 7

article

Neuroimmune signaling in neuropsychiatric disease

A. Leslie Morrow, Lawrence H. Price

Psychopharmacology > 2019 > 236 > 10 > 2855-2855

This article belongs to a Special Issue on Neuroimmune Signaling in Psychiatric Disease.

Publication date

Last 3 months (1)
Last year (5)
Last 3 years (17)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Lawrence H. Price

Lithium and the kidney

Opioids and antidepressants: When is the mantra wrong?

Pharmacogenetics and alcoholism: Reaching for the next level

Mirtazapine for anxiety in autism

Prediction is easy; change is hard

Psychopharmacology research: Pandemic reverberations

Time to demedicalize marijuana

Aducanumab: Boon or bust?

The end of the buprenorphine waiver

The perils of pandemic psychopharmacology

The ghost of Heisenberg, or: methamphetamine, again

Treating schizophrenia, part 2: What we can (almost) do now

Treating schizophrenia: What we can do now

The 2020 election commentary

The COVID‐19 commentary

Fast‐fail comes to psychopharmacology

The conundrum of antipsychotics and mortality

Memory as a therapeutic target for psychopharmacology

Treating depression: Prediction in a time of change

Neuroimmune signaling in neuropsychiatric disease

Filter options

Publication date

Content availability

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Lawrence H. Price

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options